Clinical Trials
105 trialsNCT07605962 2026-05-26
Phase 1/2 Study of UI-102 in Selected Advanced Cancers
United Immunity, co., Ltd.
Phase 1/2 Not yet recruiting
NCT06656390 2026-05-22
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2 Recruiting
NCT02797795 2026-05-13
A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers
Neovia Oncology Ltd.
Phase 1 Completed
NCT05276310 2026-04-24
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
ImmuneOncia Therapeutics Inc.
Phase 1 Recruiting
NCT03459222 2026-04-06
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Completed
NCT07269145 2026-01-28
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting
NCT03994601 2026-01-20
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04495296 2025-12-19
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 1/2 Recruiting
NCT07291050 2025-12-18
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Not yet recruiting
NCT06662760 2025-11-25
Clinical Trial of TQB3002 in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting
NCT02743494 2025-11-18
CheckMate 577
Bristol-Myers Squibb
Phase 3 Completed
NCT03369223 2025-11-18
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05025085 2025-10-15
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
Agenus Inc.
Phase 1 Completed
NCT03446040 2025-09-18
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT03900442 2025-09-02
Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort
Prescient Therapeutics, Ltd.
Phase 1 Completed
NCT06092580 2025-09-02
Phase 1 Study of AWT020 in Advanced Cancer
Anwita Biosciences
Phase 1 Recruiting
NCT04467593 2025-08-05
MATTERS
ElmediX
Phase NA Completed
NCT05735496 2025-08-01
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Active not recruiting
NCT06963814 2025-07-17
Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
HC Biopharma Inc.
Phase 1 Recruiting
NCT06188624 2025-04-25
Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting
NCT03110107 2025-04-24
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT06707610 2025-03-12
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1 Recruiting
NCT03261011 2025-02-28
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors
Akeso
Phase 1 Completed
NCT03352531 2025-02-28
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
Akeso
Phase 1 Completed
NCT06302140 2025-01-20
A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers
Viracta Therapeutics, Inc.
Phase 1 Terminated
NCT03936959 2025-01-15
A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
NCT05298592 2024-09-26
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT02944864 2024-09-23
A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Terminated
NCT01394016 2024-09-19
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT04335253 2024-09-19
First-In-Human Study of EOS884448 in Participants with Advanced Cancers.
iTeos Therapeutics
Phase 1 Completed
NCT05894421 2024-03-12
TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05154630 2024-01-18
Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Terminated
NCT00610194 2023-10-18
Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients
Bayer
Phase 1 Completed
NCT04864418 2023-07-20
AST-021p Study in Advanced Solid Tumors
Aston Sci. Inc.
Phase 1 Unknown
NCT00658671 2023-02-06
A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
CASI pharmaceuticals, Inc.
Phase 1 Completed
NCT02996110 2022-12-19
FRACTION-RCC
Bristol-Myers Squibb
Phase 2 Completed
NCT03335540 2022-09-26
ADVISE
Bristol-Myers Squibb
Phase 1 Completed
NCT02341625 2022-08-18
A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT00559182 2022-07-26
A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03312842 2022-05-26
A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1 Completed
NCT03444753 2022-05-23
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
Bristol-Myers Squibb
Phase 1 Terminated
NCT03579628 2022-03-24
DRIIV-1
Valerio Therapeutics
Phase 1 Completed
NCT03203876 2022-03-10
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT05192512 2022-03-03
Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT03792750 2022-02-28
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03475251 2022-02-18
A Study of CS1003 in Subjects With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1 Completed
NCT02737475 2022-01-25
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00687505 2021-12-13
Safety Study of FP-1039 To Treat Cancer
Five Prime Therapeutics, Inc.
Phase 1 Completed
NCT02407990 2021-11-17
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
BeiGene
Phase 1 Completed
NCT03661632 2021-11-08
An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed